Razumilava N - Search Results

1

Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.

Nadeau BA, Fecher LA, Owens SR, Razumilava N. Nadeau BA, et al. Among authors: razumilava n. Semin Liver Dis. 2018 Nov;38(4):366-378. doi: 10.1055/s-0038-1667358. Epub 2018 Oct 24. Semin Liver Dis. 2018. PMID: 30357774 Review.

2

Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future.

Likhitsup A, Razumilava N, Parikh ND. Likhitsup A, et al. Among authors: razumilava n. Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):13-19. doi: 10.1002/cld.782. eCollection 2019 Jan. Clin Liver Dis (Hoboken). 2019. PMID: 31168360 Free PMC article. Review. No abstract available.

3

Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified?

Razumilava N, Gores GJ. Razumilava N, et al. Clin Liver Dis (Hoboken). 2016 Aug;8(2):43-47. doi: 10.1002/cld.567. Epub 2016 Aug 29. Clin Liver Dis (Hoboken). 2016. PMID: 27822365 Free PMC article. No abstract available.

4

Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: Is less more?

Pan JJ, Razumilava N. Pan JJ, et al. Among authors: razumilava n. Hepatology. 2022 Mar;75(3):508-510. doi: 10.1002/hep.32330. Hepatology. 2022. PMID: 35007345 No abstract available.

5

Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y está justificada?

Razumilava N, Gores GJ. Razumilava N, et al. Clin Liver Dis (Hoboken). 2016 Nov 10;8(Suppl 1):S20-S24. doi: 10.1002/cld.602. eCollection 2016 Nov. Clin Liver Dis (Hoboken). 2016. PMID: 31041091 Free PMC article. Review. No abstract available.

6

Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet?

Shiota J, Samuelson LC, Razumilava N. Shiota J, et al. Among authors: razumilava n. Hepatology. 2021 Oct;74(4):2251-2263. doi: 10.1002/hep.31772. Epub 2021 May 28. Hepatology. 2021. PMID: 33638203 Free PMC article. Review.

7

A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.

Raevskaya O, Appelman H, Razumilava N. Raevskaya O, et al. Among authors: razumilava n. Curr Hepatol Rep. 2020 Dec;19(4):478-485. doi: 10.1007/s11901-020-00556-4. Epub 2020 Oct 31. Curr Hepatol Rep. 2020. PMID: 33415066 Free PMC article.

8

Building a staircase to precision medicine for biliary tract cancer.

Razumilava N, Gores GJ. Razumilava N, et al. Nat Genet. 2015 Sep;47(9):967-8. doi: 10.1038/ng.3386. Nat Genet. 2015. PMID: 26313225

9

Notch and mTOR Signaling Pathways Promote Human Gastric Cancer Cell Proliferation.

Hibdon ES, Razumilava N, Keeley TM, Wong G, Solanki S, Shah YM, Samuelson LC. Hibdon ES, et al. Among authors: razumilava n. Neoplasia. 2019 Jul;21(7):702-712. doi: 10.1016/j.neo.2019.05.002. Epub 2019 May 24. Neoplasia. 2019. PMID: 31129492 Free PMC article.

10

Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.

Parikh ND, Marshall VD, Green M, Lawrence TS, Razumilava N, Owen D, Singal AG, Feng M. Parikh ND, et al. Among authors: razumilava n. J Med Imaging Radiat Oncol. 2018 Oct;62(5):673-681. doi: 10.1111/1754-9485.12754. Epub 2018 Jun 7. J Med Imaging Radiat Oncol. 2018. PMID: 29877615 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page